NSCLC Clinical Trials

659 clinical trials for NSCLC across international registries, including 182 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• First in Human Study of TUB-030 in Patients With Advanced Solid Tumors — RECRUITING · PHASE1
• A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors — RECRUITING · PHASE1
• Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation — RECRUITING · PHASE3
• A Study to Assess the Efficacy and Safety of Firmonertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB - IIIB NSCLC With Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations, Following Complete Surgical Resection With or Without Adjuvant Chemotherapy（FIRMOST） — RECRUITING · PHASE3
• SKB264 in Combination With SKB118 for Non-Small Cell Lung Cancer — RECRUITING · PHASE2
• Overcoming Resistance to Immunotherapy Combining Gemcitabine With Ivonescimab in Advanced NSCLC — RECRUITING · PHASE2
• A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors — RECRUITING · PHASE1
• A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors — RECRUITING · PHASE1
• Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors — RECRUITING · PHASE4
• Oral Paclitaxel Solution With Immunotherapy and Concurrent SBRT as Neoadjuvant Treatment for Older Adults With NSCLC — RECRUITING · PHASE4
• The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) — RECRUITING · PHASE1
• A Study to Evaluate GFH375 Versus Docetaxel in Participants With Non-Small Cell Lung Cancer With KRAS G12D Mutation — RECRUITING · PHASE3
• Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023] — RECRUITING · PHASE3
• Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301) — RECRUITING · PHASE3
• A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations — RECRUITING · PHASE1
• Precise Exercise Regimen for Cancer Care (PERCC): A Pilot Study — RECRUITING · NA
• Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors — RECRUITING · PHASE1
• Targeted Induction Therapy for Stage III Unresectable EGFR Mutant Positive NSCLC — RECRUITING · PHASE2
• A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors — RECRUITING · PHASE1
• A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors — RECRUITING · PHASE1
• The Efficacy and Safety of Narlumosbart in Combination With Stereotactic Body Radiation Therapy to Improve the Efficacy of First-line Chemotherapy Combined With Immunotherapy in Patients With Bone Metastases From Advanced Non-small Cell Lung Cancer — RECRUITING · PHASE2
• Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors — RECRUITING · PHASE1
• A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers — RECRUITING · PHASE1
• Firmonertinib Combined With Definitive Radiotherapy in Stage III Unresectable EGFR Uncommon Mutant Pulmonary Adenocarcinoma — RECRUITING · PHASE2
• SKB264 Plus Glecirasib in Advanced KRAS G12C-Mutant NSCLC: A Phase II Study — RECRUITING · PHASE2
• A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC — RECRUITING · PHASE1
• A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies — RECRUITING · PHASE1
• Hypofractionated Chemoradiotherapy With Tislelizumab and Surufatinib for Unresectable Stage III NSCLC — RECRUITING · PHASE2
• RGL-270 + ICI in Advanced NSCLC — RECRUITING · NA
• Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05) — RECRUITING
• Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies — RECRUITING · PHASE2
• Study of XB010 in Subjects With Solid Tumors — RECRUITING · PHASE1
• A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer — RECRUITING · PHASE1
• Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies — RECRUITING · PHASE1
• Tislelizumab Combined With Anlotinib and Nab-paclitaxel in III Resectable Non-small Cell Lung Cancer : A Prospective, Single-Arm, Phase II Study — RECRUITING · PHASE2
• A Prospective, Multicenter, Randomized Controlled Study on the Efficacy and Safety of Low-dose Carboplatin Combined With Nab-Paclitaxel and Delayed Administration of Serplulimab as First-line Treatment for Advanced Squamous Non-small Cell Lung Cancer — RECRUITING · PHASE1
• A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression — RECRUITING · PHASE1
• A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors — RECRUITING · PHASE1
• Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors — RECRUITING · PHASE1
• A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations — RECRUITING · PHASE1
• Immune Metabolism Dysregulation and Efficacy to Anti-PD-1 PD-L1 Agents in Non Small Cell Lung Cancer Patients — RECRUITING
• Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas — RECRUITING · PHASE1
• A Phase 1/1b Study of IAM1363 in HER2 Cancers — RECRUITING · PHASE1
• Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing — RECRUITING
• Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC) — RECRUITING · PHASE2
• BBO-11818 in Adult Subjects With KRAS Mutant Cancer — RECRUITING · PHASE1
• Sub-lobectomy vs Lobectomy in IIA-IIIB NSCLC After Neoadjuvant IO+Chemo — RECRUITING · NA
• First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations — RECRUITING · PHASE1
• Safety and Efficacy of NK510 to Treat NSCLC — RECRUITING · PHASE1
• A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) Products — RECRUITING

Refine this search